Aurigene Oncology is a clinical stage biotech company focused on the discovery and development of novel and effective therapeutics for the treatment of cancer. They leverage expertise in oncology to benefit cancer patients worldwide.

Aurigene Oncology

Domain Not Resolving

Person Schema

Indian Server Location

TATA Communications

Business Management

Dinesh Chikkanna

Girish Daginakatte

Member Board of Directors

Kumar Srinivasan

Engineering

Leena Khare

Marketing and Product

Nanduri Srinivas

Sivapriya Marappan

Bablu Bablu

Finance and Administration

Bandikallu Rao

Barla Deepak

Ca Nc

Venkatesh Reddy

Founder & Deputy Manager

Murali Ramachandra

Chief Executive Officer

Karnataka Companies With More Than 10 Employees (Top 10K)

Biotechnology Companies (Top 10K)

Manufacturing Companies (Top 10K)

Asia-Pacific (APAC) Companies With More Than 100 Employees (Top 10K)

Arigene is a developer, manufacturer and marketer of Ubiquitous Healthcare Systems (U-Healthcare) and related medical equipment in Korea. With its planned acquisition of Trimeris, Inc., Arigene is expanding its business to the broader biotechnology industry.

Bangalore

Karnataka

India

Asia

Aurigene Oncology discovers new SMARCA2 and SMARCA4 degradation inducers

Aurigene Oncology presents new dual inhibitors of PD-L1 and adenosine receptors

Aurigene Oncology gets DCGI nod for phase-2 trials of CAR-T cell therapy Ribrecabtagene autoleucel

Aurigene acquires 27% stake in RE co

Biologics facility of Dr. Reddy’s CRDMO arm Aurigene opened

PKMYT1 inhibitors described in Aurigene Oncology patent

Aurigene Oncology presents new CDK12 and CDK13 inhibitors

Aurigene Oncology discovers new SMARCA2 and/or SMARCA4 degradation inducers

Aurigene Oncology discovers new MALT1 inhibitors

Aurigene inks drug discovery, development pact with US-based EQRx

An oral, small molecule dual inhibitor of PDL1 and VISTA, used in the treatment of NSCLC, bladder, and kidney cancers.

An oral, small molecule RORgt inverse agonist, developed for the treatment of moderate to severe psoriasis.

An oral, spectrum selective kinase inhibitor targeting DDR1 and SIK2, evaluated in FGFR mutant bladder cancer.

A covalent inhibitor of CDK7, in clinical evaluation for advanced solid tumors.

An oral small molecule inhibitor of CD47, showing no hemotoxicity in pre-clinical studies.

A first-in-class inhibitor of Fatty-Acid Binding Protein 5 (FABP5), evaluated as a monotherapy for NHL and CLL.

Kenya

Africa

United Kingdom

Europe

Malaysia

Germany

HTML5

Lightbox

Bootstrap

Google Analytics

jQuery

Apache Server

Amazon EC2

Office 365

Modernizr

GlobalSign

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 23, 2024 5:22 AM	fff67d60
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 23, 2024 5:22 AM	6439d7a3
crunchbase trigger	general	Nov 27, 2024 12:50 PM	734d5ef3
crunchbase profile	general	Nov 28, 2024 9:50 AM	b8f6d682
li profile	general
translate crunchbase fundingrounds	general	Nov 28, 2024 11:13 AM	7604a9ca
peers	general	Oct 23, 2024 5:22 AM	c945b8c3
news basic	general	Oct 23, 2024 5:22 AM	449e2dcc
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:AURIGENE

Aurigene Oncology